Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.
about
Mendelian randomization studies: a review of the approaches used and the quality of reportingMendelian randomization in cardiometabolic disease: challenges in evaluating causality.Leveraging human genetics to guide drug target discovery.Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk.Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levelsPlasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysisSelecting instruments for Mendelian randomization in the wake of genome-wide association studies.Novel Role for Matrix Metalloproteinase 9 in Modulation of Cholesterol Metabolism.PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.Using genetic variation for establishing causality of cardiovascular risk factors: overcoming confounding and reverse causality.Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosisThe underlying chemistry of electronegative LDL's atherogenicity.New therapies for coronary artery disease: genetics provides a blueprint.Mendelian randomisation applied to drug development in cardiovascular disease: a review.Genetic risk factors and Mendelian randomization in cardiovascular disease.Mendelian Randomization for the Identification of Causal Pathways in Atherosclerotic Vascular Disease.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.Genetics-Current and Future Role in the Prevention and Management of Coronary Artery Disease.Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis.Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical StudySecretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activationPhylogenetic and structural analysis of the phospholipase A2 gene family in vertebratesThe druggable genome and support for target identification and validation in drug development.Mendelian randomization: where are we now and where are we going?Atherosclerosis Is an Inflammatory Disease which Lacks a Common Anti-inflammatory Therapy: How Human Genetics Can Help to This Issue. A Narrative Review.Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease.Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization AnalysisBedeutung moderner Genomstudien für das HerzinfarktrisikoLp-PLA2 et sPLA2Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
P2860
Q26999349-A5BC176E-9CFC-48D8-817C-62750541871AQ30234302-12A03AE0-E884-4F41-9275-940BCC6D233DQ30245007-E23CA12C-4399-465B-8FB8-4EEDCEA4F633Q30251632-B27B7475-96D1-4906-ACFC-BF854FFAE0D1Q31053398-1A1FCC2E-96CF-459F-A7F2-17C8A062443DQ33945132-E7BE67C6-1D4E-4A2C-9486-340EEB4D650DQ34418471-F4EF171D-1F6C-4562-8352-DA4CCFCED075Q36724236-2BFF6E0C-BDE2-47D0-99F7-79D40CFFB14CQ37401173-E8737F0F-881F-4F67-8CEA-159354B69C4EQ37434796-5DFDDCB7-FCF2-4BF5-8419-D99A30826856Q37607330-F5751840-EE97-4946-B9C1-B0298A1CA1FDQ37638455-B0B7E9DE-B38D-4573-8359-80F0065D198DQ37683292-7E2D1D49-FE17-4081-A999-A7499B32E5D1Q38217088-5860B5F0-791B-4380-88F5-5D972DF74D99Q38217732-FDF141AE-01FA-4ABA-B06E-16E1F672E6FEQ38290764-76CFD57C-922B-4B92-BC89-8DB61492256FQ38430758-94CDC0B4-9473-4520-B755-7DECF2650133Q38704885-6A49F290-C1F0-4225-8463-A6AB9265A1F2Q38707328-07EF3DF8-B987-460C-A386-EA12985109D0Q38798354-EA203FB2-63EF-4FCE-9326-777FEC0C1166Q38836998-FDFA7CB3-E3CE-4B8B-B823-DEB23F747C52Q39313673-AF9E5382-44C9-4E4E-BB18-071E014E786DQ41103987-CC9C253A-DC21-4FA0-8213-0D26BA1AA78BQ41387814-3DFA1A1C-C265-44EA-918E-281653BEB063Q41645827-2938A348-E5C0-4969-9EF9-C3B18AABD2E5Q48347170-523D8327-2A1D-4266-B592-81EFC53BCF49Q48456096-73084DB2-0393-408C-B6B1-BB9ACCAFDD77Q50318400-BF6C8239-523B-466B-B6BA-78EA0AB3BCECQ52553716-0F121910-DF7B-4FDE-9341-74C78756FD2DQ57101827-3B926FAA-2D08-48A3-B0A1-16E4043189F1Q57315137-066C7786-3E6F-4FC6-A460-6BE44268F71DQ58148425-0A2B336F-2682-4FD3-919B-5AAB6E8D72EAQ59129593-52240E89-6481-47DE-A169-5EB11A064513
P2860
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Secretory phospholipase A
@nl
Secretory phospholipase A(2)-I ...... mendelian randomization study.
@en
Secretory phospholipase A(2)-I ...... mendelian randomization study.
@en-gb
type
label
Secretory phospholipase A
@nl
Secretory phospholipase A(2)-I ...... mendelian randomization study.
@en
Secretory phospholipase A(2)-I ...... mendelian randomization study.
@en-gb
prefLabel
Secretory phospholipase A
@nl
Secretory phospholipase A(2)-I ...... mendelian randomization study.
@en
Secretory phospholipase A(2)-I ...... mendelian randomization study.
@en-gb
P2093
P2860
P50
P1476
Secretory phospholipase A(2)-I ...... mendelian randomization study.
@en
P2093
Anders G Olsson
Andrew N Nicolaides
Andrie G Panayiotou
Anke H Maitland-van der Zee
Benjamin D Horne
Brendan J Keating
Christiane L Haase
Daniel J Rader
David A Morrow
P2860
P304
P356
10.1016/J.JACC.2013.06.044
P407
P50
P577
2013-07-31T00:00:00Z